Bundle Discounts from DelveInsight

Market Publishers is excited to inform that its research partner, DelveInsight, offers lucrative bundle discounts.

Purchase two or more reports prepared by this publisher and get:

  • 10% OFF the Single User License;
  • 20% OFF the Site License;
  • 30% OFF the Global License.

This bundle discount offer is valid until the end of November, 2017.

DelveInsight is a prominent provider of cutting-edge research reports featuring the biotech and pharmaceutical industries. It provides in-demand studies covering such fields as medical oncologic therapy, gene therapy, Active Pharmaceutical Ingredient (API) manufacturing, biosimilars, stem cell medication, orphan drugs, amid others.

DelveInsight supplies its customers with the most up-to-date and reliable info on the market landscape and dynamics, competitive scenario, key players, new technologies and innovations, products under development and already available in the market, etc. The company equips its clients with modern business approaches, gives a hand in decision-taking, helps to boost sales, assists in launching new products and in development of effective marketing and business strategies.

Feel free to contact our Sales Manager, Alison, at info@marketpublishers.com or reach her at +44 20 8123 2220 for any required information on bundle discounts from DelveInsight.

Found 2089 publications
Siponimod - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Siponimod, Launch Insights, 2017” report provides comprehensive insights about the Siponimod's launch. The report covers all the ... market positioning of the upcoming launch of Siponimod and will also provide the insight about how Siponimod will evolve in the market ...

Aug, 2017 50 pages
Upadacitinib - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Upadacitinib, Launch Insights, 2017” report provides comprehensive insights about the Upadacitinib's launch. The report covers all the ... market positioning of the upcoming launch of Upadacitinib and will also provide the insight about how Upadacitinib will evolve in the ...

Aug, 2017 50 pages
NuThrax - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “NuThrax, Launch Insights, 2017” report provides comprehensive insights about the NuThrax's launch. The report covers all the indications ... market positioning of the upcoming launch of NuThrax and will also provide the insight about how NuThrax will evolve in the market ...

Aug, 2017 50 pages
Acalabrutinib - Launch Insights, 2017 US$ 1,500.00

... within 48 hours DelveInsight’s, “Acalabrutinib, Launch Insights, 2017” report provides comprehensive insights about the Acalabrutinib's launch. The report covers all the ... market positioning of the upcoming launch of Acalabrutinib and will also provide the insight about how Acalabrutinib will evolve in the ...

Aug, 2017 50 pages
Brexanolone - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Brexanolone, Launch Insights, 2017” report provides comprehensive insights about the Brexanolone's launch. The report covers all the ... market positioning of the upcoming launch of Brexanolone and will also provide the insight about how Brexanolone will evolve in the ...

Aug, 2017 50 pages
AR101 - Launch Insights, 2017 US$ 1,500.00

... the clients within 48 hours DelveInsight’s, “AR101, Launch Insights, 2017” report provides comprehensive insights about the AR101's launch. The report covers all the indications ... of market positioning of the upcoming launch of AR101 and will also provide the insight about how AR101 will evolve in the market as ...

Aug, 2017 50 pages
Lanadelumab - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Lanadelumab, Launch Insights, 2017” report provides comprehensive insights about the Lanadelumab's launch. The report covers all the ... market positioning of the upcoming launch of Lanadelumab and will also provide the insight about how Lanadelumab will evolve in the ...

Aug, 2017 50 pages
Tremelimumab - Launch Insights, 2017 US$ 1,500.00

... the clients within 48 hours DelveInsight’s, “Tremelimumab, Launch Insights, 2017” report provides comprehensive insights about the Tremelimumab's launch. The report covers all the indications for ... type and mechanism of action Detailed description of non-clinical and clinical studies for all the indications ...

Aug, 2017 50 pages
Tezacaftor (VX-661) + Ivacaftor - Launch Insights, 2017 US$ 1,500.00

... of market positioning of the upcoming launch of Tezacaftor (VX-661) + Ivacaftor and will also provide the insight about how Tezacaftor (VX-661) + Ivacaftor will evolve in the market as well ...

Aug, 2017 50 pages
Emicizumab - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Emicizumab, Launch Insights, 2017” report provides comprehensive insights about the Emicizumab's launch. The report covers all the ... market positioning of the upcoming launch of Emicizumab and will also provide the insight about how Emicizumab will evolve in the market ...

Aug, 2017 50 pages
Epidiolex - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Epidiolex, Launch Insights, 2017” report provides comprehensive insights about the Epidiolex's launch. The report covers all the ... market positioning of the upcoming launch of Epidiolex and will also provide the insight about how Epidiolex will evolve in the market ...

Aug, 2017 50 pages
Elagolix - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Elagolix, Launch Insights, 2017” report provides comprehensive insights about the Elagolix's launch. The report covers all the ... market positioning of the upcoming launch of Elagolix and will also provide the insight about how Elagolix will evolve in the market ...

Aug, 2017 50 pages
MPC-150-IM - Launch Insights, 2017 US$ 1,500.00

... “MPC-150-IM, Launch Insights, 2017” report provides comprehensive insights about the MPC-150-IM's launch. The report covers all the indications for which the MPC-150-IM is ... market positioning of the upcoming launch of MPC-150-IM and will also provide the insight about how MPC-150-IM will evolve in the market ...

Aug, 2017 50 pages
Lampalizumab - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Lampalizumab, Launch Insights, 2017” report provides comprehensive insights about the Lampalizumab's launch. The report covers all the ... market positioning of the upcoming launch of Lampalizumab and will also provide the insight about how Lampalizumab will evolve in the ...

Aug, 2017 50 pages
Intepirdine - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Intepirdine, Launch Insights, 2017” report provides comprehensive insights about the Intepirdine's launch. The report covers all the ... market positioning of the upcoming launch of Intepirdine and will also provide the insight about how Intepirdine will evolve in the ...

Aug, 2017 50 pages
Aducanumab - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Aducanumab, Launch Insights, 2017” report provides comprehensive insights about the Aducanumab's launch. The report covers all the ... market positioning of the upcoming launch of Aducanumab and will also provide the insight about how Aducanumab will evolve in the market ...

Aug, 2017 50 pages
Apalutamide - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Apalutamide, Launch Insights, 2017” report provides comprehensive insights about the Apalutamide's launch. The report covers all the ... market positioning of the upcoming launch of Apalutamide and will also provide the insight about how Apalutamide will evolve in the ...

Aug, 2017 50 pages
Epacadostat - Launch Insights, 2017 US$ 1,500.00

... the clients within 48 hours DelveInsight’s, “Epacadostat, Launch Insights, 2017” report provides comprehensive insights about the Epacadostat's launch. The report covers all the indications ... its chemical properties, molecule type and mechanism of action Detailed description of non-clinical and clinical studies ...

Aug, 2017 50 pages
Ozanimod - Launch Insights, 2017 US$ 1,500.00

... clients within 48 hours DelveInsight’s, “Ozanimod, Launch Insights, 2017” report provides comprehensive insights about the Ozanimod's launch. The report covers all the ... market positioning of the upcoming launch of Ozanimod and will also provide the insight about how Ozanimod will evolve in the market ...

Aug, 2017 50 pages
Abemaciclib - Launch Insights, 2017 US$ 1,500.00

... the clients within 48 hours DelveInsight’s, “Abemaciclib, Launch Insights, 2017” report provides comprehensive insights about the Abemaciclib's launch. The report covers all the indications for ... type and mechanism of action Detailed description of non-clinical and clinical studies for all the indications ...

Aug, 2017 50 pages
Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors – Competitive Landscape, Market and Pipeline Analysis 2017 US$ 1,750.00

... “Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors – Competitive Landscape, Market and Pipeline Analysis 2017”, report provides comprehensive insights about pipeline drugs across Cyclin Dependent Kinase 4/6 inhibitors. ... report also provides the market drivers and barriers for CDK 4/6 inhibitors. The report is ...

Aug, 2017 127 pages
Hepatitis C- Competitive Landscape, Market and Pipeline Analysis 2017 US$ 3,250.00

This report can be delivered to the clients within 24 Hours DelveInsight’s, “Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017”, report provides comprehensive insights about ...

Aug, 2017 234 pages
Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast – 2027 US$ 5,750.00

... Kingdom) and Japan. To understand the future market competition in the global Nonalcoholic Steatohepatitis (NASH) market and Insightful review of the key market drivers and barriers. To understand the regulatory scenario in major ...

Jul, 2017 120 pages
Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast – 2025 US$ 5,750.00

... report provides historical as well as forecasted epidemiology of Pulmonary Arterial Hypertension (PAH) in the 7MM covering United States, European Union 5 ... the future market competition in the global Pulmonary Arterial Hypertension (PAH) market and Insightful review of the key market drivers and barriers. To ...

Jul, 2017 99 pages
Xanthine Oxidase Inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Xanthine Oxidase Inhibitor by development stage, therapy type, route of administration and molecule type is also covered in the ...

Aug, 2017 60 pages
Wnt Signaling Pathway Inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Wnt Signaling Pathway Inhibitor by development stage, therapy type, route of administration and molecule type is ... databases, primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
Voltage-Gated Sodium Channel Blockers -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Voltage-Gated Sodium Channel Blockers by development stage, therapy type, route of administration and molecule type is ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
Voltage-Dependent T-Type Calcium Channel Blockers -Pipeline Insights, 2017 US$ 1,250.00

... and discovery stage products. A comparative pipeline therapeutics assessment of Voltage-Dependent T-Type Calcium Channel Blockers by development stage, therapy type, route of administration and molecule type is ... primary and secondary research and in-house analysis by DelveInsight`s team of industry experts ...

Aug, 2017 60 pages
Voltage-Dependent Calcium Channel Blockers -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Voltage-Dependent Calcium Channel Blockers by development stage, therapy type, route of administration and molecule type ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist -Pipeline Insights, 2017 US$ 1,250.00

... and discovery stage products. A comparative pipeline therapeutics assessment of Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist by development stage, therapy type, route of administration and molecule type ... primary and secondary research and in-house analysis by DelveInsight`s team of industry experts ...

Aug, 2017 60 pages
Viral RNA Polymerase Inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Viral RNA Polymerase Inhibitor by development stage, therapy type, route of administration and molecule type is ... databases, primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... molecule-1) gene expression inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor by development ...

Aug, 2017 60 pages
Vasopressin V2 Receptor (V2R) Antagonist -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Vasopressin V2 Receptor (V2R) Antagonist by development stage, therapy type, route of administration and molecule type is ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
Vasopressin V2 Receptor (V2R) Agonist -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Vasopressin V2 Receptor (V2R) Agonist by development stage, therapy type, route of administration and molecule type is ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
Vasopressin V1 Receptor (V1R) Antagonist -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Vasopressin V1 Receptor (V1R) Antagonist by development stage, therapy type, route of administration and molecule type is ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
Vasopressin Receptor Antagonist -Pipeline Insights, 2017 US$ 1,250.00

... clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Vasopressin Receptor Antagonist by development stage, therapy type, route of administration and molecule type is also covered in the ...

Aug, 2017 60 pages
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... and discovery stage products. A comparative pipeline therapeutics assessment of Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor by development stage, therapy type, route of administration and molecule type ... primary and secondary research and in-house analysis by DelveInsight`s team of industry experts ...

Aug, 2017 60 pages
Vascular Endothelial Growth Factor Inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Vascular Endothelial Growth Factor Inhibitor by development stage, therapy type, route of administration and molecule type ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
Vascular Adhesion Protein 1 (VAP-1) Inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... and discovery stage products. A comparative pipeline therapeutics assessment of Vascular Adhesion Protein 1 (VAP-1) Inhibitor by development stage, therapy type, route of administration and molecule type ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
Ubiquitin Specific Proteases (USP) Inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Ubiquitin Specific Proteases (USP) Inhibitor by development stage, therapy type, route of administration and molecule type ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
Ubiquitin conjugating enzyme Inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Ubiquitin conjugating enzyme Inhibitor by development stage, therapy type, route of administration and molecule type is ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... and discovery stage products. A comparative pipeline therapeutics assessment of Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitor by development stage, therapy type, route of administration and molecule type is ... primary and secondary research and in-house analysis by DelveInsight`s team of industry ...

Aug, 2017 60 pages
Tumor Necrosis Factor Alpha (TNF-a) Agonist -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Tumor Necrosis Factor Alpha (TNF-a) Agonist by development stage, therapy type, route of administration and molecule type ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
TRK1-Transforming Tyrosine Kinase (Trk-A or High Affinity Nerve Growth Factor Receptor) Antagonist -Pipeline Insights, 2017 US$ 1,250.00

... discovery stage products. A comparative pipeline therapeutics assessment of TRK1-Transforming Tyrosine Kinase (Trk-A or High Affinity Nerve Growth Factor Receptor) Antagonist by development stage, therapy type, route of administration and molecule ... research and in-house analysis by DelveInsight`s team ...

Aug, 2017 60 pages
Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Antagonist -Pipeline Insights, 2017 US$ 1,250.00

... discovery stage products. A comparative pipeline therapeutics assessment of Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Antagonist by development stage, therapy type, route of administration and molecule ... and in-house analysis by DelveInsight`s ...

Aug, 2017 60 pages
Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist -Pipeline Insights, 2017 US$ 1,250.00

... discovery stage products. A comparative pipeline therapeutics assessment of Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist by development stage, therapy type, route of administration and molecule ... research and in-house analysis by DelveInsight`s ...

Aug, 2017 60 pages
Transient Receptor Potential Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist -Pipeline Insights, 2017 US$ 1,250.00

... discovery stage products. A comparative pipeline therapeutics assessment of Transient Receptor Potential Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist by development stage, therapy type, route of administration and molecule ... and secondary research and in-house analysis by DelveInsight`s team of ...

Aug, 2017 60 pages
Transient Receptor Potential Cation Channel, Subfamily A, Member 1 (TRPA1) Antagonist -Pipeline Insights, 2017 US$ 1,250.00

... discovery stage products. A comparative pipeline therapeutics assessment of Transient Receptor Potential Cation Channel, Subfamily A, Member 1 (TRPA1) Antagonist by development stage, therapy type, route of administration and molecule ... and secondary research and in-house analysis by DelveInsight`s team of ...

Aug, 2017 60 pages
Transforming Growth Factor Beta (TGFb) Inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... and discovery stage products. A comparative pipeline therapeutics assessment of Transforming Growth Factor Beta (TGFb) Inhibitor by development stage, therapy type, route of administration and molecule type ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
Transforming Growth Factor (TGF) Inhibitor -Pipeline Insights, 2017 US$ 1,250.00

... clinical and discovery stage products. A comparative pipeline therapeutics assessment of Transforming Growth Factor (TGF) Inhibitor by development stage, therapy type, route of administration and molecule type ... , primary and secondary research and in-house analysis by DelveInsight`s team of industry experts. ...

Aug, 2017 60 pages
1 2 3 4 5 next
Skip to top